Skip to main content
Marco Torregroza Otero on Muck Rack

Marco Torregroza Otero

As seen in: Nature
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Marco Torregroza

Contact Marco Torregroza, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Outcomes in KEYNOTE-355 after chemotherapy discontinuation before pembrolizumab discontinuation and with immune-mediated adverse events

|
By Hope Rugo, David W. Cescon, Peter Schmid, Zbigniew Nowecki, Seock-Ah Im, Mastura Md Yusof, Carlos Gallardo Verified, Hiroji Iwata, Oleg Lipatov, Felipe Garcia Cruz, Felipe Santa Cruz, Carlos Henrique Barrios, Roberto Hegg, Sherene Loi, Maria Gion, Péter Árkosy, Lili Yao, Jaime Mejia Verified, Wilbur Pan, Javier Cortés, Marco Torregroza Otero, Rafal Tarnawski
| Nature Verified
Abstract Pembrolizumab plus chemotherapy significantly improved progression-free survival (PFS) and overall survival (OS) versus chemotherapy in the phase 3 randomized KEYNOTE-355 study in participants with previously untreated, advanced triple-negative breast cancer (TNBC) with PD-L1 combined positive score (CPS) ≥ 10.
Open in Who Shared Issue with article?
See all 1 articles